Activated Platelet and Oxidized LDL Induce Endothelial Membrane Vesiculation: Clinical Significance of Endothelial Cell-Derived Microparticles in Patients With Type 2 Diabetes

Abstract

Endothelial cells, platelets, and oxidized LDL could play very important roles in the development of atherosclerosis in diabetes patients. The levels of plasma endothelial cell-derived microparticles (EDMP), platelet-derived microparticles (PDMP), platelet-P-selectin (plt-PS), soluble CD40 ligand (sCD40L), and anti-oxidized LDL antibody were measured and compared to develop a better understanding of their potential contribution to diabetic vascular complications. The concentrations of EDMP, PDMP, plt-PS, and sCD40L in diabetic patients were significantly higher than those in normal subjects. The number of EDMPs in patients with diabetes complicated by nephropathy was significantly higher than that in those without complications. Levels of anti-oxidized LDL antibody were also higher in type 2 diabetic patients than in control subjects. In addition, anti-oxidized LDL antibody levels correlated with EDMP, PDMP, plt-PS, and sCD40L levels in nephropathy patients. In the nephropathy group treated with sarpogrelate hydrochrolide, a 5-HT_2A receptor antagonist, EDMP, PDMP, plt-PS, and sCD40L levels were decreased significantly. Oxidized LDL increased expression of plt-PS, and also promoted shedding of PDMP. Furthermore, oxidized LDL promoted a dose-dependent release of 5-hydroxytriptamine. On the other hand, activated platelets and PDMP promoted endothelial cells and THP-1 (monocytic cell line) interaction, and membrane vesiculation occurred in the presence of oxidized LDL. These findings suggest that activated platelets and oxidized LDL induce EDMP generation, and that elevated EDMPs may be a sign of vascular complications in type 2 diabetic patients, particularly those who suffer from diabetes-associated nephropathy

Keywords

Endothelial cell-derived microparticle P-selectin Type 2 diabetes mellitus CD40 ligand Anti-oxidized LDL antibody

References

Morrish NJ , Stevens LK , Fuller JH , et al. Risk factors for macrovascular disease in diabetes mellitus: The London follow-up to the WHO multinational study of vascular disease in diabetes. Diabetologia 1991;34:590.

Donahue RP , Orchard TJ . Diabetes mellitus and macrovascular complications: An epidemiological perspective. Diabetes Care 1992;15:1141.

Borch-Johnsen K , Kreiner S. Proteinemia: Value as a predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. BMJ 1987;294:1651.

Jensen T , Borch-Johnsen K , Kofoed-Enevoldsen A , et al. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 1987;30:144.

Mattock M , Morrish N , Viberti GC , et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:735.

Steiner G. Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol 1985;189:277.

Uusitupa MI , Niskanen LK , Siitonen O , et al. Ten years cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175.

Baumgartner-Parzer SM , Wagner L , Pettermann M , et al. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells. Diabetologia 1995;38:1367.

Lampeter ER , Kishimoto TK , Rothlein R , et al. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992;41:1668.

10.

Steiner M , Reinhardt KM , Krammer B , et al. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994;72:979.

11.

Cominacini L , Pasini AF , Garbin U , et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: Relation to metabolic control. Diabetologia 1995;38:1122.

12.

Cominacini L , Pasini AF , Garbin U , et al. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: Possible role of oxidative stress. Diabetologia 1997;40:584.

13.

Nomura S , Suzuki M , Katsura K , et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995;116:235.

14.

Nomura S , Shouzu A , Omoto S , et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998;80:388.

15.

Omoto S , Nomura S , Shouzu A , et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 1999;81:271.

16.

Nomura S , Shouzu A , Omoto S , et al. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000;121:437.

17.

Johnson RB . Monocytes and macrophages. N Engl J Med 1988;318:747.

18.

Ross R. The pathogenesis of atherosclerosis: A perspective study for the 1990s. Nature 1993;362:801.

19.

Beekhuizen H , van Furth R. Monocyte adherence to human vascular endothelium. J Leukoc Biol 1993;54:363.

20.

Rodgers GM . Hemostatic properties of normal and perturbed vascular cells. FASEB J 1988;2:116.

21.

Hamilton KK , Hattori R , Esmon CT , et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990;265:3809.

22.

Combes V , Simon A , Grau G , et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104:93.

23.

Jimenez JJ , Jy W , Mauro LM , et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: Findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001;112:81.

24.

Chobanian AV . Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia co-exist. Hypertension 1991;18:130.

25.

Croft KD , Beilin LJ , Vandogen R , et al. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolaemia. Atherosclerosis 1990;83:101.

26.

Drake TA , Ruf W , Morrissey JH , et al. Functional tissue factor is entirely surface expressed on lipopolysaccharide stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol 1989;109:389.

27.

Fogelman A , Schechter I , Seager J , et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in macrophages. Proc Natl Acad Sci USA 1980;77:2214.

28.

Bellomo G , Maggi E , Poli M , et al. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995;44:60.

29.

Salonen JT , Yla-Herttuala S , Yamamoto R , et al. Autoantibodies against LDL and progression of carotid atherosclerosis. Lancet 1992;339:883.

30.

Sabatier F , Darmon P , Hugel B , et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002;51:2840.

31.

Nomura S , Suzuki M , Kido H , et al. Differences between platelet and microparticle glycoprotein IIb/IIIa. Cytometry 1992;13:621.

32.

Nomura S , Komiyama Y , Miyake T , et al. Amyloid β-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994;72:519.

33.

Miyake T , Nomura S , Komiyama Y , et al. Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Thromb Haemost 1997;78:902.

34.

Heeschen C , Dimmeler S , Hamm CW , et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndrome. N Engl J Med 2003;348:1104.

35.

Lane P , Brocker T , Hubele S , et al. Soluble CD40L can replace the normal T cell derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993;177:1209.

36.

Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248.

37.

Heller JI , Crowley JR , Hazen SL , et al. p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J Biol Chem 2000;275:9957.

38.

Jaffe EA , Nachman RL , Becker CG , et al. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1981;52:2745.

39.

Kruszynska YT , Yu JG , Olefsky JM , et al. Effects of troglitazone on blood concentrations of plasminogen activator 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633.

40.

Packham MA , Mustard JF . The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8.

41.

Nomura S. Functional and clinical significance of platelet-derived microparticles. Int J Hematol 2001;74:397.

42.

Koller E , Koller F , Binder BR . Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989;264:12412.

43.

Pedreno J , Fernandez R , Cullare C , et al. Platelet integrin αIIbβ3 (GPIIb-IIIa) is not implicated in the binding of LDL to intact resting platelets. Arterioscler Thromb Vasc Biol 1997;17:156.

44.

Hackeng CM , Huigsloot M , Pladet MW , et al. Low-density lipoprotein enhances platelet secretion via integrin-αIIbβ3-mediated signaling. Arterioscler Thromb Vasc Biol 1999;19:239.

45.

van Willigen G , Gorter G , Akkerman JW . LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994;14:41.

46.

Surya II , Gorter G , Mommersteeg M , et al. Enhancement of platelet functions by low density lipoproteins. Biochim Biophys Acta 1992;1165:19.

47.

Ardlie NG , Selley ML , Simons LA . Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989;76:117.

48.

Merten M , Dong JF , Lopez JA , et al. Cholesterol sulfate. A new adhesive molecule for platelets. Circulation 2001;103:2032.

49.

Zhao B , Dierichs R , Harrach-Ruprecht B , et al. Oxidized LDL induces serotonin release from blood platelets. Am J Hematol 1985;48:285.

50.

Shouzu A , Nomura S , Hayakawa T , et al. Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus. Clin Appl Thromb Hemost 2000;6:139.

51.

Springer TA . Adhesion receptors of the immune system. Nature 1990;346:425.

52.

Bevilacqua MP . Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993;1:767.

53.

Libby P. Atheroma: More than mush. Lancet 1996;348:s4.

54.

Sawamura T , Kume N , Aoyama T , et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73.

55.

Kume N , Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994;93:907.

56.

Kugiyama K , Kerns SA , Morrisett JD , et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160.